NGeneBio Completes Massive 66.67% Capital Reduction, Share Consolidation Reshapes Shareholder Value
NGeneBio completed its capital reduction on June 29, 2026, reducing outstanding shares from 26,809,750 to 8,936,583, a 66.67% decrease.
The reduction applied equally to major and minority shareholders, preserving ownership percentages. The par value remains 1,000 won, while the capital stock decreased from 26,809,750,000 won to 8,936,583,000 won.
The effective date of the reduction is June 25, 2026, with the changed listing expected on July 13, 2026. The consolidation aims to boost per-share value and improve the financial structure.
[AI Summary]NGeneBio's 66.67% capital reduction drastically cuts the number of shares, raising expectations for higher per-share value and improving financial health. However, the impact of reduced capital should be monitored. Short-term price trends are expected to stabilize post-listing change.